• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SLITRK6 基因的差异表达可作为尿路上皮癌特别是上尿路移行细胞癌的潜在治疗靶点。

Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.

机构信息

Department of Urology, Sheri-Kashmir Institute of Medical Sciences, (SKIMS), Srinagar 190011, J&K, India.

Department of Advanced Centre for Human Genetics, SKIMS, Srinagar 190011, J&K, India.

出版信息

Gene. 2023 Aug 20;878:147583. doi: 10.1016/j.gene.2023.147583. Epub 2023 Jun 22.

DOI:10.1016/j.gene.2023.147583
PMID:37353040
Abstract

BACKGROUND

Urinary bladder urothelial carcinoma (UBUC) and upper tract urothelial carcinoma (UTUC) harbor analogous morphology with comparable cytogenetic changes as well as prognostic factors but their similar biological activities still remain controversial. SLITRK6 gene has been demonstrated to have distinct role in urothelial cancers with a distinction between UTUC and UBUC.

METHOD

The study included a total of 80 patients of urothelial carcinoma including 60 UBUC and 20 UTUC cases. The tumor tissues from both the groups were evaluated for gene expression at mRNA level by qRT-PCR, and protein expression by immunohistochemistry (IHC) and western blot.

RESULTS

Significantly more than 4-fold high mRNA expression of SLITRK6 was observed in UTUC against 1.2-fold in UBUC (p < 0.0001). The overall SLITRK6 expression by IHC was observed in 80% of the UBUC cases in comparison to 100% strong expression in UTUC patients and among two groups expression exhibited a significant difference for moderate to strong expression (p = 0.0005). The protein expression by western blot analysis in UTUC samples was considerably higher as compared to UBUC samples (1.64 vs. 0.76 respectively: p = 0.01). A strong concordance exhibited for the higher mRNA and protein expression in both UTUC and UBUC cases (∼75%) wherein 80%, 75% and 70% higher expression of SLITRK6 was detected by qRT-PCR, Western blot and IHC respectively.

CONCLUSION

To conclude, although SLITRK6 exhibits a strong expression in both UTUC and UBUC but was considerably observed higher in majority of UTUC cases. Therefore, SLITRK6 appears as a promising novel possible gene target for urothelial carcinoma in particular UTUC.

摘要

背景

膀胱尿路上皮癌(UBUC)和上尿路尿路上皮癌(UTUC)具有相似的形态学特征,具有类似的细胞遗传学改变和预后因素,但它们的相似生物学活性仍存在争议。SLITRK6 基因在尿路上皮癌中具有明显的作用,能够区分 UTUC 和 UBUC。

方法

本研究共纳入 80 例尿路上皮癌患者,其中 UBUC 患者 60 例,UTUC 患者 20 例。采用 qRT-PCR 检测两组患者肿瘤组织的基因表达水平,采用免疫组织化学(IHC)和 Western blot 检测蛋白表达水平。

结果

UTUC 中 SLITRK6 的 mRNA 表达水平明显高于 UBUC,是 UBUC 的 4 倍以上(p<0.0001)。IHC 检测显示,80%的 UBUC 病例存在 SLITRK6 表达,而 100%的 UTUC 患者存在强烈表达,两组间表达差异具有统计学意义(p=0.0005)。UTUC 样本的 Western blot 分析显示,蛋白表达明显高于 UBUC 样本(分别为 1.64 和 0.76:p=0.01)。UTUC 和 UBUC 病例的 mRNA 和蛋白表达均具有较强的一致性(∼75%),其中 qRT-PCR、Western blot 和 IHC 分别检测到 SLITRK6 的表达水平分别高出 80%、75%和 70%。

结论

总之,尽管 SLITRK6 在 UTUC 和 UBUC 中均有较强的表达,但在大多数 UTUC 病例中表达更高。因此,SLITRK6 似乎是一种有前途的新型尿路上皮癌特别是 UTUC 的潜在基因靶点。

相似文献

1
Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.SLITRK6 基因的差异表达可作为尿路上皮癌特别是上尿路移行细胞癌的潜在治疗靶点。
Gene. 2023 Aug 20;878:147583. doi: 10.1016/j.gene.2023.147583. Epub 2023 Jun 22.
2
High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.几丁质酶 3 样蛋白 1 高表达是上尿路尿路上皮癌和膀胱癌的预后不良因素。
Urol Oncol. 2019 May;37(5):299.e7-299.e18. doi: 10.1016/j.urolonc.2019.01.001. Epub 2019 Jan 17.
3
IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.IGFBP-5 过表达是上尿路和膀胱尿路上皮癌患者预后不良的一个因素。
J Clin Pathol. 2013 Jul;66(7):573-82. doi: 10.1136/jclinpath-2012-201278. Epub 2013 Mar 28.
4
Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.RNF128的下调预示上尿路和膀胱尿路上皮癌患者的病情进展及不良预后。
J Cancer. 2016 Oct 25;7(15):2187-2196. doi: 10.7150/jca.16798. eCollection 2016.
5
MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.MCM10过表达提示尿路上皮癌预后不良。
Oncotarget. 2016 Nov 22;7(47):77777-77792. doi: 10.18632/oncotarget.12795.
6
Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.硫酸酯酶-1过表达提示膀胱及上尿路尿路上皮癌预后不良。
Oncotarget. 2017 Jul 18;8(29):47216-47229. doi: 10.18632/oncotarget.17590.
7
The metabolic syndrome is associated with the risk of urothelial carcinoma from a health examination database.代谢综合征与健康检查数据库中尿路上皮癌的风险相关。
Int J Clin Oncol. 2021 Mar;26(3):569-577. doi: 10.1007/s10147-020-01834-3. Epub 2020 Nov 24.
8
CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.CSF2过表达与尿路上皮癌患者的STAT5磷酸化及不良预后相关。
J Cancer. 2016 Mar 26;7(6):711-21. doi: 10.7150/jca.14281. eCollection 2016.
9
Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.二氢嘧啶酶样 3(DPYSL3)蛋白上调预示着尿路上皮癌预后不良。
BMC Cancer. 2023 Jun 28;23(1):599. doi: 10.1186/s12885-023-11090-z.
10
SPOCK1 Overexpression Confers a Poor Prognosis in Urothelial Carcinoma.SPOCK1 过表达与膀胱癌不良预后相关。
J Cancer. 2016 Jan 29;7(4):467-76. doi: 10.7150/jca.13625. eCollection 2016.

引用本文的文献

1
Machine Learning-Based Gene Expression Analysis to Identify Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.基于机器学习的基因表达分析以鉴定上尿路尿路上皮癌的预后生物标志物
Cancers (Basel). 2025 Aug 11;17(16):2619. doi: 10.3390/cancers17162619.
2
Insight into the Association between Slitrk Protein and Neurodevelopmental and Neuropsychiatric Conditions.解析 Slitrk 蛋白与神经发育和神经精神疾病之间关联的研究进展。
Biomolecules. 2024 Aug 26;14(9):1060. doi: 10.3390/biom14091060.
3
Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.
尿路上皮癌中的抗体药物偶联物:科学计量学分析与临床试验分析
Front Oncol. 2024 Mar 14;14:1323366. doi: 10.3389/fonc.2024.1323366. eCollection 2024.
4
Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.重新审视替莫唑胺联合放射治疗和组蛋白去乙酰化酶抑制剂丙戊酸治疗胶质母细胞瘤的疗效——基于蛋白组学改变的患者,并与标准放化疗进行比较分析。
Biomolecules. 2023 Oct 10;13(10):1499. doi: 10.3390/biom13101499.